Nice post BKC. That's a really interesting hypothesis about RVX-208, royalty rights, and the RVX/Zenith AGMs.

That's also really interesting about the GSK patent. Interest in bromodomain inhibition is really heating up. I sure am glad Resverlogix and Zenith are at the forefront of this. No guarantee that bromodomain inhibition will pass clinical trials for cancer, cardio, etc. But if it does, Resverlogix and Zenith have carved themselves out as leaders in this field.

BearDownAZ